Wave Life Sciences grants Takanashi 64,000 options

The 64,000-share option award has a $3.75 exercise price and expires October 5, 2036.

Rhea-AI Filing Summary

Wave Life Sciences, Inc. (WVE) director Ken Takanashi received a 10,700-share restricted stock unit award and an option award covering 64,000 shares on October 5, 2026. Both awards vest 100% on the earlier of the company’s 2027 annual meeting of stockholders or October 5, 2027. After the RSU award, Takanashi directly held 30,779 common shares. SNBL USA, Ltd. and Shin Nippon Biomedical Laboratories, Ltd. were reported as holding shares indirectly; Takanashi disclaimed beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

Grant/Award: 74,700 shares

Grant/Award 3 txns

Insider TAKANASHI KEN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F2	64,000	$0.00	$0.00
Grant/Award	Common Stock F1	10,700	$0.00	$0.00
holding	Common Stock F3, F4	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 64,000 contracts (Direct); Common Stock — 30,779 shares (Direct); Common Stock — 9,606,408 shares (Indirect, See Footnote)

Footnotes (4)

1. F1. The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
2. F2. The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
3. F3. Includes an aggregate of (i) 6,107,593 shares of common stock held by SNBL USA, Ltd. ("SNBL USA") and (ii) 3,498,815 shares of common stock held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL").
4. F4. Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL.

Key Figures

Restricted stock unit award: 10,700 shares Option award: 64,000 shares Option exercise price: $3.75 per share +5 more

8 metrics

Restricted stock unit award 10,700 shares Granted to Ken Takanashi on October 5, 2026

Option award 64,000 shares Granted to Ken Takanashi on October 5, 2026

Option exercise price $3.75 per share Exercise price for the option award

Direct common shares following RSU award 30,779 shares Ken Takanashi’s reported direct holdings

Option expiration date October 5, 2036 Expiration date of the option award

Shares held by SNBL USA, Ltd. 6,107,593 shares Common shares held by the entity

Shares held by Shin Nippon Biomedical Laboratories, Ltd. 3,498,815 shares Common shares held by the entity

Award vesting 100% Both awards vest on the earlier of the company’s 2027 annual meeting of stockholders or October 5, 2027

Key Terms

restricted stock unit award (RSU), Non-Employee Director Compensation Policy, pecuniary interest, beneficial ownership

4 terms

restricted stock unit award (RSU) financial

"granted this restricted stock unit award (RSU)"

Non-Employee Director Compensation Policy financial

"pursuant to the 2026 Non-Employee Director Compensation Policy"

pecuniary interest financial

"except to the extent of his pecuniary interest therein"

beneficial ownership regulatory

"disclaims beneficial ownership of the reported securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What awards did WVE director Ken Takanashi receive?

Ken Takanashi received a 10,700-share restricted stock unit award and an option award covering 64,000 shares on October 5, 2026. Both awards vest in full on the earlier of the company’s 2027 annual meeting of stockholders or October 5, 2027. The options have a $3.75 exercise price and expire October 5, 2036.

How many WVE shares did SNBL USA and Shin Nippon Biomedical Laboratories hold?

SNBL USA, Ltd. held 6,107,593 shares of Wave Life Sciences common stock, and Shin Nippon Biomedical Laboratories, Ltd. held 3,498,815 shares. Ken Takanashi disclaimed beneficial ownership of these entity-held shares except to the extent of his pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 09:00 PM Accepted by SEC EDGAR 10/07/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TAKANASHI KEN

(Last) (First) (Middle)

C/O SHIN NIPPON BIOMEDICAL LABORATORIES,

2438 MIYANOURA-MACHI, KAGOSHIMA CITY

(Street)

KAGOSHIMA JAPAN 891-1394

(City) (State) (Zip)

JAPAN

(Country)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences, Inc. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/05/2026		A		10,700(1)	A	$0	30,779	D
Common Stock								9,606,408(3)	I	See Footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.75	10/05/2026		A		64,000		(2)	10/05/2036	Common Stock	64,000	$0.00	64,000	D

Explanation of Responses:

1. The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

2. The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

3. Includes an aggregate of (i) 6,107,593 shares of common stock held by SNBL USA, Ltd. ("SNBL USA") and (ii) 3,498,815 shares of common stock held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL").

4. Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL.

	/s/ Ken Takanashi	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)